Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Clinical Trial of ssCART-19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

NCT06367114 is registered in ClinicalTrials.gov with Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd as lead sponsor.

NCT NCT06367114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06367114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Clinical Trial of ssCART-19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Lead sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2024
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute lymphoblastic leukemia